Benralizumab Inhibits Upper Airway Expression of Thymic Stromal Lymphopoietin in Severe Asthma
Clinical & Experimental Allergy · 2026-10-30
DOI: 10.1111/cea.70468 ↗At a glance
Journal article in Clinical & Experimental Allergy, published online on 2026-10-30. Written by Hazel Marriott and 5 co-authors. Institution: Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada. 9 references. The full text is freely available (open access, CC BY 4.0). Funded by: AstraZeneca Canada.
Abstract (original language)
Treatment with benralizumab significantly reduced nasal TSLP in patients with severe asthma. Nasal TSLP shows potential as a pharmacodynamic biomarker, pending validation in larger, randomized studies.
Authors and institutions
- Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Bagchi School of Public Health, Ahmedabad University, Ahmedabad, India.
ORCID profiles: Hazel Marriott, Marc Duchesne, Jalal Moolji, Adil Adatia, Subhabrata Moitra, Paige Lacy
Funding
- AstraZeneca Canada
Cite
APA
Marriott, H., Duchesne, M., Moolji, J., Adatia, A., Moitra, S., & Lacy, P. (2026). Benralizumab Inhibits Upper Airway Expression of Thymic Stromal Lymphopoietin in Severe Asthma. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70468
Vancouver
Marriott H, Duchesne M, Moolji J, Adatia A, Moitra S, Lacy P. Benralizumab Inhibits Upper Airway Expression of Thymic Stromal Lymphopoietin in Severe Asthma. Clinical & Experimental Allergy. 2026. doi:10.1111/cea.70468
BibTeX
@article{Marriott2026,
author = {Marriott, Hazel and Duchesne, Marc and Moolji, Jalal and Adatia, Adil and Moitra, Subhabrata and Lacy, Paige},
title = {Benralizumab Inhibits Upper Airway Expression of Thymic Stromal Lymphopoietin in Severe Asthma},
journal = {Clinical & Experimental Allergy},
year = {2026},
doi = {10.1111/cea.70468}
}
EUVIMED